Europe DNA Sequencing Market

Europe DNA Sequencing Market Size (2023 to 2028)

The European DNA sequencing market size is forecasted to showcase a CAGR of 18.4% between 2023 to 2028.

DNA sequencing is employed in various applications, including biomarker identification, oncology research, personalized treatment, forensics, and more. Due to a growth in sequencing applications, a rise in the number of genome mapping programs throughout the world, increasing R&D expenditure, and technological advancements in DNA sequencing, demand for DNA sequencing has increased significantly. Bioinformatics developments, growing prevalence of viral infections like SARS and COVID-19, increased applications of NGS (Next-generation Sequencing) and WGS (Whole-genome Sequencing), and growing cancer incidences globally are fueling the European DNA sequencing market expansion. Due to technical developments in DNA sequencing platforms, cloud computing applications to store DNA sequencing data, data storage & management, and other fields, DNA sequencing and the biotechnology sector are becoming more prominent. The overall market is predicted to rise for the following reasons: increased research and development activities employing NGS technologies, expanding uses of NGS in clinical diagnostics, and discovery applications requiring NGS technology.

The growth of the DNA sequencing market may be hindered by issues about accuracy and standards, as well as ethical and legal restrictions. Social and ethical issues, bioinformatics constraints, a shortage of skilled professionals, and diagnostic testing accuracy are among the market growth restraints. The market for next-generation sequencing is encountering hurdles since many customers cannot afford the test due to its high price. Therefore, the high cost of next-generation sequencing technology is a major obstacle to the market's expansion.

COVID-19 Impact on the Europe DNA Sequencing Market:

The disease has spread to almost every country globally since the COVID-19 virus outbreak in December 2019, prompting the World Health Organization to declare it a public health emergency. For many healthcare reimbursement facilities, DNA sequencing is likely to become more popular throughout the forecast period. As a result of these, next-generation sequencing is expected to become more widely used in healthcare diagnostics. In March 2020, a COVID-19 genome sequencing partnership was created for large-scale viral analysis. The market is expected to increase substantially during the forecast period (2023 to 2028), owing to the rising DNA sequencing-based research and development efforts in the development of diagnostic tools or effective therapies for COVID-19. Next-generation sequencing (NGS) technique for qualitative identification of SARS-CoV-2 nucleic acid in upper respiratory specimens from people suspected of having COVID-19. Throughout the COVID-19 epidemic, governments worldwide have collaborated with the private sector to bring next-generation sequencing (NGS) technology to market as a viable diagnostic tool.

This research report on the European DNA sequencing market has been segmented and sub-segmented into the following categories.

By Product & Services:

• Consumables
• Instruments
• Services

By Technology:

• Sanger Sequencing
• Next-Generation Sequencing
• Whole Genome Sequencing (WGS)
• Whole Exome Sequencing (WES)
• Targeted Sequencing & Resequencing
• Third Generation DNA Sequencing  
• Single-Molecule Real-Time Sequencing (SMRT)
• Nanopore Sequencing

By Workflow:

• Pre-sequencing
• Sequencing
• Data Analysis

By Application:

• Oncology
• Reproductive Health
• Clinical Investigation
• Agri genomics & Forensics
• HLA Typing/Immune System Monitoring
• Metagenomics, Epidemiology & Drug Development
• Consumer Genomics
• Others

By End-use:

• Academic Research
• Clinical Research
• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Other Users

By Country:

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

Geographically, Due to the growing rates of an aging population suffering from cancer, sedentary lifestyle, and an efficient reimbursement scenario, the European DNA sequencing market is expected to drive the growth of the DNA Sequencing Market in the coming years. The presence of skilled researchers and high investment in research and development made Europe the most significant market. Germany has made significant investments in healthcare and medical research in response to the rising prevalence of diseases. The German DNA sequencing market is expected to grow as a result of this. Pharmaceutical and biotechnology businesses in Italy are increasing their market share and making major expenditures to meet the growing demand for DNA sequencing. The fast-paced expansion of the R&D sector and industry-wide partnerships focusing on a variety of applications and research activities are expected to contribute to market expansion. In addition, the government's preference for home care services and educational initiatives is expected to aid in driving high incontinence device market income to this region.

KEY MARKET PLAYERS:

Agilent Technologies, Inc., Abbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), F. Hoffmann-La Roche Ltd, Illumina, Inc., LI-COR Biosciences, Inc., Pacific Biosciences of California, Inc., SIEMENS AG, PerkinElmer Inc., and Thermo Fisher Scientific, Inc. are a few of dominating companies in the Europe DNA sequencing market.